Clinical trials: LPA
Heterozygous Familial Hypercholesterolemia
Lp(a) and Aortic Valve Calcification
Aortic valve stenosis (AVS), the most common form of valve disease in the western world, afflicts more than 1 million individuals in North America [1] and the burden of AVS is high and is expected to double within the next 50…
- Trial name
- FHLPA (NCT02976818)
- Where
- Canada
- Volunteers
- 173 people
- Sponsor
- Laval University
Elevated Lipoprotein(a)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)
The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of ISIS-APO(a)Rx given to participants with high lipoprotein(a) for 12 weeks.
- Trial name
- NCT02160899
- Testing
- ISIS-APO(a)Rx
- Where
- 13 sites in Canada, Denmark and 3 more
- Volunteers
- 64 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Coronary Artery Disease (CAD)
Lipoprotein a Assessment and Relation to Ca Score in CAD Patients Using MSCT
The goal of this observational study is to evaluate whether serum Lipoprotein(a) [Lp(a)] levels are associated with coronary artery calcium (CAC) score measured by multi-slice computed tomography (MSCT) in adults undergoing…
- Trial name
- NCT07184034
- Volunteers
- 150 people
- Sponsor
- Assiut University
Ischemic Heart Disease, Coronary Artery Disease
Electronic Letters to Improve Patient Activation in IHD: The NUDGE-IHD Trial
The goal of this clinical trial is to learn whether simple electronic information letters can increase patient activation and improve risk-factor monitoring in adults in Denmark with ischemic heart disease (IHD) who have LDL…
- Conditions
- Ischemic Heart Disease, Coronary Artery Disease, Hypercholesterolemia, Lipoprotein(a)
- Trial name
- NUDGE-IHD (NCT07382414)
- Testing
- LDL-C information letter, Lp(a) information letter
- Where
- Denmark
- Volunteers
- 123,000 people
- Sponsor
- Tor Biering-Sørensen
Lipoprotein(a), Lipoprotein-apheresis
Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patients With Chronic Kidney Disease ; ( LiPo-A )
Lipoprotein-apheresis DFPP has been performed in patients with Lp(a) levels greater than 125 nmol/L. In this report, data will be presented on five hemodialysis patients with significantly elevated Lp(a) levels (>200 nmol/L) who…
- Conditions
- Lipoprotein(a), Lipoprotein-apheresis, Double-filtration Plasmapheresis, Hemodialysis Complication
- Trial name
- LiPo-A (NCT07390604)
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Atherosclerotic Cardiovascular Disease
Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia
This study has the purpose to answer how the Lipoprotein(a) (Lp(a)) level is distributed among Atherosclerotic cardiovascular disease (ASCVD) patients in Russia, and what is the connection between elevated levels of this…
- Trial name
- STaRT (NCT06858332)
- Testing
- Atorvastatin, Simvastatin, Rozuvastatin
- Where
- 20 sites in Russia
- Volunteers
- 2,382 people
- Sponsor
- Novartis Pharmaceuticals
Elevated Lp(a)
A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)
A study in males and females with elevated Lp(a) to look at the effects of TA-8995 on Lp(a) levels.
- Trial name
- NCT02241772
- Testing
- TA-8995
- Where
- Denmark
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Xention Ltd
PCI
Prognostic Role of Lipoprotein(a) in Elective Percutaneous Coronary Revascularization
The study investigates the role of Lipoprotein(a) [Lp(a)] levels in predicting cardiovascular risk and adverse events in patients undergoing elective percutaneous coronary intervention (PCI).
- Trial name
- NCT07197242
- Volunteers
- 156 people
- Sponsor
- Assiut University
Lipoprotein(a), Hyper-Lp(a)-Emia
The Prevalence of Hyper-Lp(a)-Emia in the PMMHRI-Lp(a) Registry
The PMMHRI-Lp(a)-Registry is a non-interventional, single-center registry conducted in the Polish Mother's Memorial Hospital Research Institute (PMMHRI). The PMMHRI-Lp(a)-Registry was established in January 2022.
- Trial name
- NCT06610669
- Where
- Poland
- Volunteers
- 2,000 people
- Sponsor
- Polish Mother Memorial Hospital Research Institute
Primary Progressive Aphasia(PPA), Progressive Aphasia
Remotely-supervised Neuromodulation in PPA
The goal of this clinical trial is to learn whether home-based brain stimulation combined with virtual speech-language therapy can improve communication abilities in adults with logopenic variant primary progressive aphasia…
- Conditions
- Primary Progressive Aphasia(PPA), Progressive Aphasia, Progressive Aphasia in Alzheimer's Disease, Logopenic Progressive Aphasia (LPA)
- Trial name
- NCT07260253
- Testing
- Lexical Retrieval Cascade Treatment, Remotely Supervised Transcranial Direct Current Stimulation- Active
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Maya Henry
Atherosclerosis, Cardiovascular Diseases
A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk
Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart disease.
- Conditions
- Atherosclerosis, Cardiovascular Diseases, Lipoprotein(a)
- Trial name
- ACCLAIM-CTA (NCT07613294)
- Testing
- Lepodisiran
- Where
- 58 sites in United States, Australia and 5 more
- Volunteers
- 252 people
- Sponsor
- Eli Lilly and Company
Lipoprotein Disorder, Arterial Stiffness
The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Myocardial Deformation
1. Introduction Lipoprotein(a), or Lp(a), is a type of lipoprotein that is structurally similar to LDL (low-density lipoprotein) but carries an additional protein called apolipoprotein (a). 2.
- Conditions
- Lipoprotein Disorder, Arterial Stiffness, Endothelial Dysfunction
- Trial name
- Lpa_endo (NCT07324902)
- Where
- 2 sites in Greece
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Athens
Healthy Participants, Elevated Lp(a)
SAL0137 Phase I Study in in Healthy Participants With or Without Elevated Lp(a)
This study is divided into 3 parts: Part A, Part B, and Part C. Part A is a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of…
- Trial name
- NCT07745114
- Testing
- Single Ascending Dose, Once Daily (QD), Multiple Ascending Dose (MAD)
- Where
- China
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Acute Coronary Syndrome, Lipoprotein Disorder
Role of LipoprotEin(a) in CardiovascuLar Diseases and Premature Acute Coronary Syndromes - (RELACS) Study
Several clinical and preclinical studies have focused interest on lipoprotein(a) [Lp(a)], showing a direct and independent relationship of its circulating levels with the progression of atherosclerosis and its clinical…
- Conditions
- Acute Coronary Syndrome, Lipoprotein Disorder, Acute Myocardial Infarction, Cardiovascular Diseases
- Trial name
- RELACS (NCT05496790)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- University of Campania Luigi Vanvitelli
Aortic Stenosis and Lipoprotein(a) Levels
Early Aortic Valve Lipoprotein(a) Lowering Trial
Aortic valve disease is the most common form of heart valve disease and is a major burden to society. Aortic valve disease is also expected to become more prevalent with the aging of the Canadian population.
- Trial name
- EAVaLL (NCT02109614)
- Testing
- Extended release Niacin
- Where
- 3 sites in Canada
- Sponsor
- George Thanassoulis
Lipoprotein (a)
Lipid Screening Study
The purpose of this pilot study is to estimate the prevalence of elevated Lipoprotein (a) in an adult primary care population and to describe the distribution of atherogenic lipid markers within this cohort.
- Trial name
- NCT07579325
- Testing
- Venipuncture
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Central Florida
Atherosclerotic Cardiovascular Disease
Pelacarsen Roll-over Extension Program
This non-randomized, rollover extension study will provide post-trial access to pelacarsen (TQJ230) to participants who have successfully completed either of the double-blind parent studies (CTQJ230A12303 or CTQJ230A12304).
- Trial name
- NCT06875973
- Testing
- Pelacarsen (TQJ230)
- Where
- 89 sites in United States, Puerto Rico
- Volunteers
- 599 people
- Sponsor
- Novartis Pharmaceuticals
Adult Participants With Elevated Lipoprotein(a)
A Phase II Clinical Study of SYH2068 Injection in Adults With Elevated Lipoprotein(a)
The purpose of this study is to evaluate the efficacy and safety of SYH2068 injection in patients with elevated lipoprotein(a).
- Trial name
- NCT07640217
- Testing
- SYH2068 Dose 1, SYH2068 Dose 2, SYH2068 Dose 3
- Volunteers
- 120 people
- Sponsor
- CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Lipoprotein Disorder
Study of Oral HRS-5346 in Adult Patients With Elevated Lipoprotein(a) and High Risk of Cardiovascular Events
This study is designed to evaluate the efficacy and safety of HRS-5346 Tablets in participants with high cardiovascular event risk and elevated Lp(a), and to investigate the appropriate dosage of HRS-5346 Tablets
- Trial name
- NCT07767513
- Testing
- HRS-5346
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Cardiovascular Disease
Clinical Study to Assess High-DHA Fish Oil on Biomarkers of Cardiovascular Disease Risk in Adults on Statin Therapy
The objective of this study is to determine the acute and chronic [4-week] effects of a high-DHA fish oil supplement on fasting and post-prandial (post-meal) biomarkers of cardiovascular disease risk, in adults on Statin therapy.
- Trial name
- NCT01690312
- Testing
- Fish Oil
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Nutrasource Pharmaceutical and Nutraceutical Services, Inc.